Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2021-04-10 Regulatory Filings
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-04-10 English
Prospectus (non pricing) supplement (ATM) – English.pdf
Regulatory Filings
2021-04-10 English
Consent letter of underwriters' legal counsel.pdf
Regulatory Filings Classification · 95% confidence The document is a letter of consent from a law firm (Blake, Cassels & Graydon LLP) regarding a prospectus supplement dated April 9, 2021, related to a short form base shelf prospectus for the offering of common shares by Sona Nanotech Inc. It confirms the firm's consent to the use of their opinion and name in the prospectus supplement. The document is not the prospectus itself but a legal consent letter related to a financing document. It does not contain financial statements or detailed financial data, nor is it a report or announcement of voting results, management changes, or earnings. It is related to a capital raising activity (offering of common shares). However, since it is a consent letter and not the actual financing update or prospectus, it is best classified under Regulatory Filings (RNS) as a miscellaneous regulatory document that does not fit other categories. The document length is short (2160 characters), and it is a formal regulatory filing letter rather than a report or announcement.
2021-04-10 English
Consent letter of issuer's legal counsel.pdf
Regulatory Filings Classification · 95% confidence The document is a letter of consent from a legal firm regarding references to their opinions in a Shelf Prospectus Supplement dated April 9, 2021. It is addressed to multiple securities commissions and confirms no misrepresentations in the Prospectus. The document does not contain financial data, report content, or detailed financial statements. It is a regulatory filing related to a prospectus but is not the prospectus itself or a financial report. The document length is short (1715 characters), and it serves as a consent letter, which fits best under Regulatory Filings (RNS).
2021-04-10 English
Auditors' consent letter.pdf
Regulatory Filings Classification · 95% confidence The document is a consent letter from the independent auditor Manning Elliott LLP addressed to various Canadian securities commissions regarding the use of their audit report in a Prospectus Supplement dated April 9, 2021. It references the auditor's report on financial statements for fiscal years ended October 31, 2020 and 2019. The document explicitly states it is a consent to use the auditor's report in a prospectus and clarifies that this consent does not constitute an audit or review of the prospectus itself. The document length is short (2254 characters) and it does not contain actual financial statements or substantive financial data, only a consent related to an audit report. According to the rules, such a document is an auditor's consent letter and should be classified as a Regulatory Filing (RNS), not as an Audit Report (AR) or Annual Report (10-K).
2021-04-10 English
Underwriting or agency agreements (or amendment thereto).pdf
Regulatory Filings
2021-04-10 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.